Australia's TGA issues class-wide GLP-1 eye safety warnings

Australia's Therapeutic Goods Administration issued a Medicines Safety Update on July 23, 2026, titled "GLP-1 RAs and rare vision disorder," announcing that warnings about non-arteritic anterior ischemic optic neuropathy, or NAION, will be added across the entire class of GLP-1 receptor agonist medicines sold in Australia ^[2]. The agency advised that anyone who experiences sudden vision changes while on these drugs should get medical attention right away ^[1].

NAION is damage to the optic nerve caused by reduced blood flow. It can cause sudden vision loss that usually does not hurt, sometimes in just one eye ^[1]. It is a separate condition from diabetic retinopathy, which involves damage to blood vessels in the retina and can sometimes get temporarily worse when blood sugar drops quickly in people who already have retinal disease ^[1].

Australia's move follows earlier action by other regulators. The UK's Medicines and Healthcare products Regulatory Agency issued a drug safety update on semaglutide products and NAION risk, and the European Medicines Agency's safety committee concluded in 2025 that NAION should be listed as a very rare side effect of semaglutide medicines, including Ozempic, Rybelsus, and Wegovy ^[1][2]. The World Health Organization also issued a notice on semaglutide and NAION risk in June 2025 ^[2]. The EMA's review estimated roughly one additional NAION case per 10,000 person-years of treatment, and cited epidemiologic estimates suggesting close to a two-fold increase in relative risk among adults with type 2 diabetes ^[1].

Despite this pattern of international regulatory action, the current US prescribing information for Ozempic, revised as of May 2026, does not include a warning about NAION or other eye side effects ^[2]. That gap has become the basis for product liability lawsuits filed against Novo Nordisk in the US by people who developed NAION while using Ozempic, alleging the company failed to warn about the risk ^[2]. Those lawsuits are being brought against the manufacturer, not against prescribing doctors, specifically because no such warning currently appears on the US label ^[2].

Research on the retina side of the question is mixed. A 2026 systematic review found that findings on diabetic retinopathy across GLP-1 studies were inconsistent, and that apart from a signal seen in the SUSTAIN-6 trial, most randomized trials did not show increased retinopathy progression ^[1]. The SUSTAIN-6 trial itself, published in 2016, reported more diabetic retinopathy complications with semaglutide than placebo in a high-risk group of people with diabetes, a result some researchers link to rapid improvement in blood sugar rather than the drug itself ^[1].

Why it matters for patients

For US patients, the practical reality is a mismatch: regulators in Australia, the UK, and the European Union have moved to flag NAION risk on drug labels or safety communications, but the Ozempic label used by US prescribers has not been updated to include that warning as of mid-2026 ^[1][2]. This means US patients may not see NAION mentioned in their prescribing information even though international regulators consider it a recognized, if very rare, risk ^[1].

The core message from clinicians writing about this issue is that sudden vision loss, a dark curtain across part of the vision, or a new blind spot are not symptoms to wait out until a routine appointment; they call for urgent evaluation ^[1]. People with diabetes, existing retinopathy, high vascular risk, or a history of NAION are described as needing closer coordination between prescribers and eye specialists, though no universal extra eye-screening schedule has been established for all patients simply because they take a GLP-1 medicine ^[1].

It is not yet known whether or when the FDA will require a NAION warning on the US Ozempic label, or whether the warning will extend to other GLP-1 products marketed in the US ^[2].

What happens next

The TGA's July 23, 2026 update calls for class-wide label changes in Australia, though a timeline for when those changes take effect on individual product labels is not specified in the available material ^[2]. Litigation against Novo Nordisk over alleged failure to warn is ongoing in the US, with a case evaluation process open to people diagnosed with NAION after Ozempic use ^[2]. Whether the FDA will follow the EMA, MHRA, WHO, and TGA in updating US labeling remains an open question as of this writing ^[2].